Mount Yale Investment Advisors LLC Sells 172 Shares of BioNTech SE (NASDAQ:BNTX)

Mount Yale Investment Advisors LLC lessened its holdings in BioNTech SE (NASDAQ:BNTX) by 8.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,879 shares of the company’s stock after selling 172 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in BioNTech were worth $214,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Fred Alger Management LLC bought a new stake in BioNTech in the third quarter valued at about $59,485,000. Baillie Gifford & Co. grew its stake in shares of BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock valued at $986,750,000 after purchasing an additional 31,773 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of BioNTech by 63.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock worth $2,249,000 after buying an additional 7,340 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock worth $15,919,000 after buying an additional 74,119 shares during the period. Finally, SG Americas Securities LLC boosted its stake in BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock valued at $4,726,000 after buying an additional 33,375 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BNTX shares. TD Cowen cut their price objective on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a report on Tuesday, November 5th. Berenberg Bank began coverage on shares of BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target for the company. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. Canaccord Genuity Group lifted their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research note on Wednesday, November 27th. Finally, The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their price target for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $142.72.

BioNTech Price Performance

Shares of BNTX stock opened at $121.16 on Thursday. The firm has a market cap of $29.05 billion, a price-to-earnings ratio of -57.69 and a beta of 0.18. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average price of $116.88 and a 200 day moving average price of $106.67.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the previous year, the company earned $0.73 EPS. BioNTech’s revenue was up 38.9% on a year-over-year basis. Research analysts expect that BioNTech SE will post -3.77 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.